FORMULATION · HYDROXYAPATITE · ORAL-CARE EVIDENCE
Toothpaste tablets deserve serious science.
DOTS is developing fluoride-free toothpaste tablets with nano-hydroxyapatite (n-HAp) as a planned active ingredient. Here is what published evidence says—and where its limits remain.
NOT SLOGANS ✳
A familiar mineral. A studied oral-care ingredient.
Hydroxyapatite is a calcium-phosphate mineral that forms the principal inorganic component of tooth enamel and dentin.
Hydroxyapatite particles are studied for interactions with enamel surfaces, including deposition and remineralisation-related outcomes. Nano-hydroxyapatite refers to a particle-size form; particle size, morphology, concentration, purity and the complete formulation all matter.
DOTS intends to use n-HAp in a fluoride-free toothpaste tablet. Final concentration, grade, particle specifications and complete ingredient declaration will be published only after the commercial formula and label are approved.
Evidence for one hydroxyapatite product cannot automatically be transferred to another. Ingredient-level research is not a clinical trial of the finished DOTS tablet.
02 — WHAT THE RESEARCH SAYS
Promising evidence. Careful conclusions.
A 2024 systematic review and meta-analysis identified 18 eligible studies, including five clinical trials and eight in-situ trials. It reported an expanding evidence base for hydroxyapatite-containing, fluoride-free oral-care products and caries-related outcomes. The authors disclosed relevant industry relationships and travel-grant support.
A 2025 systematic review focused on in-situ randomised trials in people under 25. Only four studies met its eligibility criteria. It found no statistically significant difference between fluoride-free HAP and fluoride toothpaste for pooled caries-progression outcomes assessed. This does not establish that all HAP products are equivalent to fluoride toothpaste.
A 2026 review mapping fluoride-free alternatives concluded HAP has the most consistent evidence among fluoride-free categories, while also noting that the evidence base remains limited and does not match fluoride’s long-term caries-prevention evidence in children.
What we can say—and what we cannot.
We will not claim that DOTS prevents cavities, repairs enamel, reverses decay or is clinically equivalent to fluoride toothpaste without appropriate finished-product evidence and regulatory review.
Published studies examine specific formulations, concentrations, particle grades, populations and protocols. Fluoride toothpaste has a substantial evidence base for caries prevention. A fluoride-free choice should be made with an understanding of individual caries risk and professional dental advice—particularly for children and people at elevated risk.
Read the research.
Clinical evidence of caries prevention by hydroxyapatite: an updated systematic review and meta-analysis. Journal of Dentistry, 2024.
PubMed ↗
The role of hydroxyapatite-based, fluoride-free toothpastes on prevention and remineralisation of initial caries lesions. Journal of Dentistry, 2025. Four eligible in-situ trials in participants under 25.
Review ↗
Navigating fluoride hesitancy: mapping the evidence base for fluoride-free toothpaste alternatives. 2026 systematic evidence map.
PubMed ↗
Comparative efficacy of a hydroxyapatite and a fluoride toothpaste for prevention and remineralisation of dental caries in children. BDJ Open, 2019; 14-day in-situ crossover study.
Study ↗
Educational summary, not treatment advice. The cited studies do not evaluate the final DOTS formulation. Last reviewed October 2026.